

Special Issue

Management of CIN and HPV Eradication Strategies for the Prevention of Uterine Cervical Cancer

Message from the Guest Editor

In this Special Issue, the main aim is to help to prevent uterine cervical cancer. For the prevention of uterine cervical cancer, there are two categories, i.e., primary and secondary prevention. As primary prevention of uterine cervical cancer, HPV vaccines are used for the prevention of HPV infection worldwide. As secondary prevention of uterine cervical cancer, diagnosis and management of CIN is performed. We are interested in a broad area of research, focusing primarily on the management of CIN and HPV eradication strategies for the prevention of uterine cervical cancer. In addition, we are calling for manuscripts dealing with vaccine trials (preclinical and clinical) and strategies to develop a more effective HPV vaccine. We aim to present a combination of manuscripts dealing with different vital aspects of HPV, which can be exploited to develop more effective eradication strategies for HPV infection.

Guest Editor

Dr. Masaru Sakamoto

1. Department of Gynecology, Sasaki Foundation Kyoundo Hospital, Tokyo 101-0062, Japan
2. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan

Deadline for manuscript submissions

closed (31 January 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/45358

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).